# Staccato Loxapine in Agitation (Proof of Concept)

> **NCT00369577** · PHASE2 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 129 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Inhaled Placebo
- **DRUG:** Inhaled Loxapine 5 mg
- **DRUG:** Inhaled Loxapine 10 mg

## Key facts

- **NCT ID:** NCT00369577
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2018-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369577, "Staccato Loxapine in Agitation (Proof of Concept)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00369577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*